Lutz Naehrlich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5815927/publications.pdf

Version: 2024-02-01

51 papers	4,225 citations	257450 24 h-index	175258 52 g-index
54 all docs	54 docs citations	54 times ranked	4814 citing authors

#	Article	IF	Citations
1	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children â‰¥Â6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis, 2022, 21, 675-683.	0.7	10
2	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 540-549.	5.6	78
3	Defective BACH1/HO-1 regulatory circuits in cystic fibrosis bronchial epithelial cells. Journal of Cystic Fibrosis, 2021, 20, 140-148.	0.7	10
4	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Journal of Cystic Fibrosis, 2021, 20, 68-77.	0.7	37
5	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
6	Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry. Journal of Cystic Fibrosis, 2021, 20, e87-e92.	0.7	6
7	Altered relaxation times in MRI indicate bronchopulmonary dysplasia. Thorax, 2020, 75, 184-187.	5.6	22
8	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
9	Infection prevention and control in patients with cystic fibrosis (CF): Results from a survey in 35 German CF treatment centers. Journal of Cystic Fibrosis, 2020, 19, 384-387.	0.7	4
10	The Changing Face of Cystic Fibrosis and Its Implications for Screening. International Journal of Neonatal Screening, 2020, 6, 54.	3.2	10
11	Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. ERJ Open Research, 2020, 6, 00408-2020.	2.6	18
12	Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Scientific Reports, 2020, 10, 18999.	3.3	30
13	Have courage in using nasal potential difference for diagnostic decisions and clinical research. Journal of Cystic Fibrosis, 2020, 19, 507-508.	0.7	0
14	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	10.7	114
15	Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1238-1248.	5.6	96
16	Effects of Lumacaftorâ€“Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1433-1442.	5.6	95
17	Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 114-121.	11.4	53
18	Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. Orphanet Journal of Rare Diseases, 2018, 13, 42.	2.7	33

#	Article	IF	Citations
19	Three-center feasibility of lung clearance index in infants and preschool children with cystic fibrosis and other lung diseases. Journal of Cystic Fibrosis, 2018, 17, 249-255.	0.7	33
20	Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 518-527.	0.7	68
21	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
22	Cystic Fibrosis. Deutsches Ärzteblatt International, 2017, 114, 564-574.	0.9	49
23	Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS ONE, 2017, 12, e0178784.	2.5	29
24	Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Genetics in Medicine, 2016, 18, 333-340.	2.4	37
25	Cystic fibrosis transmembrane conductance regulator biomarkers in â€˜real lifeâ€™: can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?. Therapeutic Advances in Respiratory Disease, 2015, 9, 198-200.	2.6	1
26	Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?. Journal of Cystic Fibrosis, 2015, 14, 310-316.	0.7	9
27	Misdiagnosis of Cystic Fibrosis Based on Transient Pancreatic Insufficiency and Elevated Sweat Chloride. Klinische Padiatrie, 2015, 227, 96-97.	0.6	1
28	High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study. PLoS ONE, 2014, 9, e112578.	2.5	49
29	Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a caseâ€“control study. BMC Pulmonary Medicine, 2014, 14, 156.	2.0	18
30	Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2014, 13, 24-28.	0.7	34
31	Is there evidence for correct diagnosis in cystic fibrosis registries?. Journal of Cystic Fibrosis, 2014, 13, 275-280.	0.7	14
32	Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease. PLoS ONE, 2014, 9, e115847.	2.5	14
33	A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging. Pediatric Radiology, 2013, 43, 552-557.	2.0	26
34	Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients. Journal of Trace Elements in Medicine and Biology, 2013, 27, 122-125.	3.0	14
35	Individualized vitamin A supplementation for patients with cystic fibrosis. Clinical Nutrition, 2013, 32, 805-810.	5.0	25
36	Misdiagnosis of cystic fibrosis â€” Experience from Germany. Journal of Cystic Fibrosis, 2013, 12, 68-73.	0.7	11

#	Article	IF	Citations
37	Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study. Cellular Physiology and Biochemistry, 2013, 31, 505-512.	1.6	1,925
38	Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease. PLoS ONE, 2013, 8, e58955.	2.5	30
39	Diabetes in Cystic Fibrosis: Multicenter Screening Results Based on Current Guidelines. PLoS ONE, 2013, 8, e81545.	2.5	22
40	Neonatal Cystic Fibrosis Screening. Deutsches Ärzteblatt International, 2013, 110, 354-5.	0.9	2
41	Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy and Asthma Proceedings, 2012, 33, 77-81.	2.2	10
42	TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. Digestive and Liver Disease, 2012, 44, 780-787.	0.9	26
43	Serine Proteases Degrade Airway Mucins in Cystic Fibrosis. Infection and Immunity, 2011, 79, 3438-3444.	2.2	56
44	Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax, 2009, 64, 535-540.	5.6	169
45	Sweat testing in CF. Thorax, 2007, 62, 462-462.	5.6	5
46	Functional Characterization of a Novel CFTR Mutation P67S Identified in a Patient with Atypical Cystic Fibrosis. Cellular Physiology and Biochemistry, 2007, 19, 239-248.	1.6	8
47	Endoscopic Cystogastrostomy of a Pancreatic Retention Cyst in Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 477-478.	1.8	2
48	Balloon Dilation of an Esophageal Stenosis in a Patient with Recessive Dystrophic Epidermolysisâ€ƒBullosa. Pediatric Dermatology, 2000, 17, 477-479.	0.9	9
49	Langzeitbeatmung respirator-abhÃngiger Kinder mit schweren AtemregulationstÃ¶rungen bei Myelomeningozele und Chiari-II-Malformation. Monatsschrift Fur Kinderheilkunde, 2000, 148, 837-840.	0.1	2
50	Prader-Willi-Syndrom. Monatsschrift Fur Kinderheilkunde, 1997, 145, 515-518.	0.1	1
51	Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Frontiers in Pharmacology, 0, 13, .	3.5	33